Zai Lab - ADR Peer Comparison

$25.07

$-1.37 (-5.18%)

As on 24-Sep-2026 13:38EDT

Market cap

$2,885 Mln

Revenue (TTM)

$450 Mln

P/E Ratio

--

P/B Ratio

4.7

Div. Yield

0 %

Edit

	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Silence Therapeutics PLC (SLN)	Pharming Group N.V. ADS each representing 10 (PHAR)
Market cap ($ Mln)	2,885	2,376	1,965	758	747
Revenue ($ Mln)	450	549	121	1	366
Net Profit ($ Mln)	-188.21	17.88	-57.76	-59.95	9.27
Net Margin (%)	-41.86	3.26	-47.60	-9,759.23	2.53
RoE (%)	-28.46	1.43	-9.91	-118.98	3.39
Price to Earnings	--	136.70	--	--	75.36
Price-To-Book	4.75	1.91	3.40	20.57	2.82

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Silence Therapeutics PLC (SLN)	Pharming Group N.V. ADS each representing 10 (PHAR)
Operating Revenue	449.61	549.12	120.79	0.61	366.45
Cost of Revenue	195.71	548.01	19.21	0.30	49.36
Gross Profit	269.08	212.72	12.07	0.34	330.63
Operating Expenses	517.90	35.89	154.86	67.15	304.74
Operating Profit (EBIT)	-264.00	-34.78	-118.11	-66.84	12.35
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-190.72	20.08	-57.14	-59.95	15.84
Provision for Tax	-2.51	1.66	0.62	0.00	6.57
Profit after Tax (Net Income)	-188.21	17.88	-57.50	-59.95	9.27
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	0.00	0.00	0.00	0.00

Liabilities ($ Mln)

	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Silence Therapeutics PLC (SLN)	Pharming Group N.V. ADS each representing 10 (PHAR)
Shareholder's Funds	607.04	1,260.78	568.41	38.47	270.49
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	39.17	186.25	123.56	55.23	104.25
Current Liabilities	428.58	275.21	81.11	12.71	93.25
Total Liabilities	1,172.38	1,753.10	784.68	131.44	499.81

Assets ($ Mln)

	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Silence Therapeutics PLC (SLN)	Pharming Group N.V. ADS each representing 10 (PHAR)
Non-Current Assets	160.76	183.02	575.59	12.13	187.30
Current Assets	914.04	1,553.41	197.49	94.28	280.69
Total Assets	1,172.38	1,753.10	784.68	131.44	499.81
Total Debt*	254.58	94.51	127.33	0.11	113.30
Net Current Assets	485.45	0.00	116.38	81.57	187.44

Cashflow ($ Mln)

	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Silence Therapeutics PLC (SLN)	Pharming Group N.V. ADS each representing 10 (PHAR)
Cash From Operating Activities	-150.79	-64.66	-49.95	-62.27	54.71
Cash Flow from Investing Activities	307.87	-29.41	0.12	-47.99	26.25
Cash from Financing Activities	72.35	7.84	147.34	0.02	1.50
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Silence Therapeutics PLC (SLN)	Pharming Group N.V. ADS each representing 10 (PHAR)
ROCE (%)	-18.15	41.92	-15.42	-104.49	0.77
ROE (%)	-28.46	1.43	-10.06	-118.98	3.39
ROA (%)	-12.55	0.66	-6.60	-40.08	1.69
EBIT Margin (%)	-41.09	-6.33	-42.43	-9,892.63	8.34
Net Margin (%)	-41.86	3.26	-47.60	-9,759.23	2.53
Cash Profit Margin (%)	0.00	--	--	-0.02	0.00

Growth Ratios

	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Silence Therapeutics PLC (SLN)	Pharming Group N.V. ADS each representing 10 (PHAR)
Revenue Growth (%)	5.10	-8.81	602.33	-97.63	-99.61
EBIT Growth (%)	11.36	-76.55	17.93	26.29	523.06
Net Profit Growth (%)	11.44	-96.17	43.71	31.30	-99.68
EPS Growth (%)	-1.87	-96.17	47.43	31.24	-96.78
Book Value Growth (%)	-25.05	2.54	-6.65	-59.14	7.71

Valuation Ratios

	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Silence Therapeutics PLC (SLN)	Pharming Group N.V. ADS each representing 10 (PHAR)
Price / Earnings	-11.11	5.08	-13.58	-1.08	469.58
Price / Book Value	2.73	1.88	2.32	1.54	4.83
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	-9.39	-25.58	-18.38	-0.12	36.65
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Silence Therapeutics PLC (SLN)	Pharming Group N.V. ADS each representing 10 (PHAR)
Debt to Equity	0.00	0.00	0.19	0.00	0.34
Short term debt to equity ratio	0.40	0.02	0.02	0.00	0.03
Current Ratio	2.13	5.64	2.43	7.42	3.01
Quick Ratio	1.92	5.50	2.09	7.42	2.31
Interest Coverage	-30.87	-19.05	-4.06	--	2.08

Operating Efficiency Ratios

	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Silence Therapeutics PLC (SLN)	Pharming Group N.V. ADS each representing 10 (PHAR)
Debtors to sales (%)	16.23	21.41	47.25	1,512.64	15.55
Asset Turnover	0.30	0.20	0.14	0.00	0.67
Receivable days	77.60	104.79	380.35	8,295.02	51.78
Inventory Days	109.55	49.57	791.94	--	492.02
Payable days	231.78	47.68	931.00	6,253.37	466.91
Cash Conversion Cycle	-44.63	106.67	241.30	--	76.89

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly